Highly active antiretroviral therapy (HAART) has dramatically reduced mortality and
morbidity in HIV-infected persons in developed countries. Although the use of HAART …

Access to highly active antiretroviral therapy (HAART) for persons infected with HIV in sub-
Saharan Africa has greatly improved over the past few years. However, data on long-term …

Objectives: To analyse the association between the presence of resistance mutations and
treatment outcomes. The impact of HIV-1 drug resistance mutations in African adults on …

Here we review the available evidence on adherence to highly active antiretroviral therapy
(HAART) and its relationship with the risk of the dissemination of HIV-resistant viral strains in …

Background: Recent reports showed the high vulnerability for HIV infection of men who have
sex with men (MSM) in Africa. Here, we report the HIV-1 variants that circulate among MSM …

Background The classification of HIV-1 strains in subtypes and Circulating Recombinant
Forms (CRFs) has helped in tracking the course of the HIV pandemic. In Senegal, which is …

Objective: HIV mutation accumulation has great implications for pharmacoeconomics and
clinical care, yet scarcity of data has hindered its representation in decision analytic models …

Non‐B HIV subtypes have been estimated to account for 88% of HIV infections in the world.
These subtypes are particularly relevant in view of the availability of antiretroviral (ARV) …

Antiviral drugs that act at specific sites within the HIV life cycle have important rationale for
development as anti-HIV microbicides. However, to be effective, such drugs must act by …

Current HIV-1 antiretroviral (ARV) drug resistance knowledge is limited to HIV-1 subtype B
(HIV-1B). We addressed whether unique genetic and phenotypic properties of HIV-1 …